PULBOROUGH MEDICAL GROUP
SPIRO CLOSE, PULBOROUGH
HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2010 | 10 | 16 | 62.5% | |
| HF 4 | 2011 | 11 | 14 | 78.6% | |
| HF 4 | 2012 | 15 | 20 | 75.0% | |
| HF 4 | 2013 | 17 | 23 | 73.9% | |
| HF004 | 2014 | 4 | 5 | 80.0% | |
| HF004 | 2015 | 5 | 6 | 83.3% | |
| HF004 | 2016 | 5 | 6 | 83.3% | |
| HF004 | 2017 | 8 | 9 | 88.9% | |
| HF004 | 2018 | 7 | 9 | 77.8% | |
| HF004 | 2019 | 7 | 7 | 100.0% | |
| HF004 | 2020 | 10 | 12 | 83.3% | |
| HF006 | 2021 | 15 | 20 | 75.0% | |
| HF006 | 2022 | 19 | 19 | 100.0% | |
| HF006 | 2023 | 32 | 33 | 97.0% |
